Persistent PSA, which is defined as PSA ≥ 0.1 ng/mL within 4–8 weeks after RP, is considered to be associated with worse tumor outcomes such as cancer progression, biochemical recurrence, and cancer-specific mortality, leading to a worse prognosis if interventions are delayed [4,5,6,7,8]. Here, KLK3 is linked to cancer.